# Alliance for Clinical Trials in Oncology: Phase 3 study closed enrollment, 760 enrolled (Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | Alliance for Clinical Trials in Oncology |
| Sponsor type | Academic and hospital |
| Study | Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response |
| NCT ID | NCT05610163 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Stage II Rectal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Locally Advanced Rectal Adenocarcinoma |
| Intervention types | drug, radiation, procedure |
| Target enrollment | 760 |
| Site countries | United States, Puerto Rico |
| Posted | 2022-11-09 |
| Planned start | 2022-12-08 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-09-25 |
| Last update posted | 2026-09-25 |

## Why this score
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 760 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05610163). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.